Having Led FY2026, 4DMedical Shares Today’s ASX 200 Laggard: The Latest

4DMedical shares (ASX:4DX) have started FY27 as the ASX 200’s worst performer, closing 10.82% lower at A$4.04, as markets demanded proof of revenue growth following last year’s spectacular but polarising re-rating.

The 4DX share price fell back A$0.49 today, moving firmly negative on a YTD basis, down 11.01% since the start of calendar 2026. The sharp reversal marks a dramatic shift from FY26, when 4DMedical skyrocketed 1,786% to close at A$4.53, briefly touching an all-time high of A$7.55 in April. The gains came almost entirely in the first half of the financial year, with the stock consolidating through the second half despite continued operational announcements.

What had been driving 4DMedical shares?

The catalyst for 4DMedical’s extraordinary FY26 performance was the September 2025 FDA 510(k) clearance for CT:VQ, the world’s first non-contrast, post-processing technology that transforms routine chest CT scans into quantitative ventilation and perfusion maps. The breakthrough positioned 4DMedical as a potential disruptor in the multi-billion-dollar pulmonary embolism and chronic lung disease diagnostic market, offering hospitals a software-as-a-service alternative to traditional nuclear medicine VQ scans.

Following FDA approval, the company secured deployments at some of the United States’ most prestigious medical institutions, including Mayo Clinic, Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, and the University of Miami. The blue-chip customer roster, combined with a strategic partnership that saw Philips market CT:VQ through its thousand-strong sales force, fuelled investor enthusiasm and drove the stock’s meteoric rise.

By the first quarter of FY26, 4DMedical reported approximately 409 sites globally, up 51% year-on-year, processing around 74,000 scans, representing 106% growth. The company highlighted software gross margins exceeding 90%, reinforcing the high-operating-leverage SaaS economics at the heart of its investment thesis.

In January 2026, riding the momentum of its elevated share price, 4DMedical completed a substantial capital raise of approximately A$150 million through an institutional placement. Management earmarked the funds to accelerate US rollout, support large-scale health system implementations, and deepen research and development efforts. The raise left the company with an estimated A$200 million in cash, eliminating near-term funding concerns.

Revenue Versus Valuation

Price Targets

While operational metrics continued to trend positively, financial results revealed the gap between early-stage adoption and the revenue scale implied by the stock’s valuation. The FY25 annual report showed total income of approximately A$16–17 million with ongoing net losses and negative equity. First-quarter FY26 operating revenue came in at around A$1.4 million, reflecting the nascent commercialisation phase.

Subsequent quarterly updates through the first half of calendar 2026 showed contract wins and scan volumes climbing, but some analysts and investors viewed revenue growth as underwhelming relative to the expectations built by the share price move and the company’s messaging around a US$2.5 billion addressable market in PE imaging alone. Under commercial contracts, 4DMedical targets approximately US$500 per scan as its SaaS share of the roughly US$650 reimbursement hospitals receive, implying software gross margins near 99% at scale. The question for markets is how quickly “at scale” arrives.

As the stock ran more than tenfold and then pulled back, short interest increased materially. Daily volatility has been extreme, with single-session swings of 8–10% commonplace through the second half of FY26. The elevated short interest and technical overhang appear to have contributed to today’s sharp decline, as profit-taking at financial year-end intersected with a broader risk-off rotation away from high-multiple healthcare and technology names.

What Comes Next: The “Prove-It” Phase

The investment debate entering FY27 has shifted from euphoria to execution.

Bulls argue that CT:VQ’s clinical validation is unambiguous, the funding is in place, and the company is simply in the early innings of a long adoption curve across a vast, under-served market. They point to the prestigious reference sites, the Philips channel leverage, ongoing discussions around potential US Veterans Affairs adoption, and expanding pharma partnerships as evidence of multiple growth vectors. Additional regulatory approvals in Europe, the UK, Canada, and Australia would further support the bull case.

Bears counter that the current valuation remains rich relative to near-term revenue, with the stock trading at very high price-to-sales multiples and no path to profitability in the immediate quarters ahead. They highlight execution risk in converting pilot programs into scaled, high-throughput commercial contracts, and express concern that management’s communications have at times led sentiment rather than fundamentals.

4DMedical shares’ journey from speculative medical technology play to ASX 200 constituent has been volatile. Whilst today’s action is a single session sample, the optics of a flip from index leader through FY26, to FY27 laggard could cause bulls to sweat a little more than they might like.

The company has undeniably achieved a significant regulatory and clinical milestone with CT:VQ, securing a foothold in world-class institutions and positioning itself at the forefront of a potentially transformative shift in respiratory imaging. Yet today’s 11% decline serves as a stark reminder that markets will ultimately demand financial proof to justify elevated valuations, and that the gap between clinical validation and commercial scale can be wide, uncertain, and volatile.